Filing Flows › Pacira BioSciences (PCRX) › Q3 2026 › vs Q3 2025
Pacira BioSciences (PCRX) Q3 2026 vs Q3 2025 (year over year)
Pacira BioSciences's revenue fell $2.9M (-2%) from $180M in Q3 2025 to $177M in Q3 2026. The biggest changes: Bupivacaine liposome injectable suspension −$1.5M (-56%); Net product sales +$120K (+0.1%). Operating margin 12.6% against 3.5% (+9.1 pts).
Pacira BioSciences, Q3 2026: revenue $177M (-2% year over year), operating margin 12.6%, net earnings $28.5M, operating cash flow $50.1M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Operating margin | 12.6% | 3.5% | +9.1 pts |
| Net margin | 16.1% | 3.0% | +13.1 pts |
| Free cash flow margin | 26.3% | 31.7% | -5.4 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| EXPAREL | $143M | $140M | $2.6M | +2% |
| ZILRETTA | $29.8M | $29.0M | $778K | +3% |
| iovera° | $2.0M | $6.5M | −$4.5M | -69% |
| Service | $1.2M | $0 | $1.2M | — |
| Net product sales | $175M | $175M | $120K | +0.1% |
| Bupivacaine liposome injectable suspension | $1.2M | $2.7M | −$1.5M | -56% |
| Revenue | $177M | $180M | −$2.9M | -2% |
| Other income, net | $6.5M | $3.2M | $3.4M | +107% |
| Operating profit | $22.3M | $6.4M | $15.9M | +250% |
| Costs & expenses | $154M | $173M | −$18.8M | -11% |
| Pre-tax earnings | $28.8M | $9.5M | $19.3M | +203% |
| Cost of revenue | $37.2M | $34.3M | $3.0M | +9% |
| Research & development | $26.7M | $26.0M | $716K | +3% |
| SG&A | $83.8M | $91.8M | −$8.0M | -9% |
| Other operating costs | $6.6M | $21.1M | −$14.5M | -69% |
| Net earnings | $28.5M | $5.4M | $23.1M | +425% |
| Income tax | $293K | $4.1M | −$3.8M | -93% |
| Depreciation & amortization | $19.3M | $21.2M | −$1.9M | -9% |
| Share-based compensation | $11.8M | $14.0M | −$2.2M | -15% |
| Working capital & other | $9.5M | −$20.2M | $29.8M | — |
| Operating cash flow | $50.1M | $60.8M | −$10.8M | -18% |
| Free cash flow (OCF − capex) | $46.4M | $57.0M | −$10.5M | -18% |
| Capital expenditures | $3.6M | $3.9M | −$245K | -6% |
Questions
How much did Pacira BioSciences's revenue grow year over year in Q3 2026?
Pacira BioSciences's revenue fell $2.9M (-2%) from $180M in Q3 2025 to $177M in Q3 2026.
What drove Pacira BioSciences's revenue change in Q3 2026?
Bupivacaine liposome injectable suspension −$1.5M (-56%); Net product sales +$120K (+0.1%).